102. Rubinstein-Taybi syndrome Clinical trials / Disease details


Clinical trials : 3 Drugs : 8 - (DrugBank : 1) / Drug target genes : 7 - Drug target pathways : 17

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04122742
(ClinicalTrials.gov)
October 8, 20199/10/2019Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.Rubinstein-Taybi SyndromeProcedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.;Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy;Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations;Other: Functional involvement of identified epigenetic alterations;Biological: Culture of lymphoblastoid line from blood sampleUniversity Hospital, BordeauxNULLRecruiting6 YearsN/AAll154France
2NCT01619644
(ClinicalTrials.gov)
April 201212/6/2012Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic TrialRubinstein-Taybi Syndrome: Functional Imaging and Therapeutic TrialRubinstein-Taybi SyndromeDrug: sodium valproate;Drug: PlaceboUniversity Hospital, BordeauxFondation Syndrome de Rubinstein-TaybiCompleted6 Years21 YearsBoth41Phase 2France
3EUCTR2011-003784-30-FR
(EUCTR)
13/12/2011Rubinstein-Taybi syndrome: approach to functional imaging and therapeutic trialRubinstein-Taybi syndrome: approach to functional imaging and therapeutic trial - RUBIVAL Rubinstein-Taybi Syndrome
MedDRA version: 14.1;Level: PT;Classification code 10039281;Term: Rubinstein-Taybi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: DepakineCHU de bordeauxNULLNAFemale: yes
Male: yes
Phase 2France